Comparison of fluorodeoxyglucose uptake in symptomatic carotid artery and stable femoral artery plaques

British Journal of Surgery

Volumn 101, Issue 4, 2014, Pages 363-370

  Shaikh, S ^a   Welch, A ^a   Ramalingam, S L ^b   Murray, A ^a   Wilson, H M ^a   McKiddie, F ^b   Brittenden, J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; ENDARTERECTOMY; FEMALE; FEMORAL ARTERY; HUMAN; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LEG; MACROPHAGE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; THROMBOEMBOLISM; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAROTID STENOSIS; CEREBROVASCULAR DISORDERS; ENDARTERECTOMY; ENDARTERECTOMY, CAROTID; FEMALE; FEMORAL ARTERY; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LEG; MACROPHAGES; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THROMBOEMBOLISM;

EID: 84894028678     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9403     Document Type: Article

References (42)

1. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R,. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30: 1282-2129.
2. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke 1998; 29: 1625-1630. (Pubitemid 28365585)
3. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T,. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
4. Rogers IS, Tawakol A,. Imaging of coronary inflammation with FDG-PET: feasibility and clinical hurdles. Curr Cardiol Rep 2011; 13: 138-144.
5. 18F]- fluorodeoxyglucose positron emission tomography. Circulation 2002; 105: 2708-2711. (Pubitemid 34615139)
6. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007; 50: 892-896. (Pubitemid 47268746)
7. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong et al. Atherosclerosis inflammation imaging with 18 F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008; 49: 871-878. (Pubitemid 351793426)
8. Arauz A, Hoyos L, Zenteno M, Mendoza R, Alexanderson E,. Carotid plaque inflammation detected by 18 F-fluorodeoxyglucose-positron emission tomography. Pilot study. Clin Neurol Neurosurg 2007; 109: 409-412. (Pubitemid 46660336)
9. Davies JR, Izquierdo-Garcia D, Rudd JH, Figg N, Richards HK, Bird JL, et al. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. Int J Cardiovasc Imaging 2010; 26: 41-25.
10. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18 F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48: 1818-1824. (Pubitemid 44648622)
11. Graebe M, Pedersen SF, Borgwardt L, Højgaard L, Sillesen H, Kjaer A,. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg 2009; 37: 714-721.
12. Font MA, Fernandez A, Carvajal A, Gamez C, Badimon L, Slevin M, et al. Imaging of early inflammation in low-to-moderate carotid stenosis by 18-FDG-PET. Front Biosci (Landmark Ed) 2009; 14: 3352-3360.
13. Masteling MG, Zeebregts CJ, Tio RA, Breek JC, Tietge UJ, de Boer JF, et al. High-resolution imaging of human atherosclerotic carotid plaques with micro 18 F-FDG PET scanning exploring plaque vulnerability. J Nucl Cardiol 2011; 18: 1066-1075.
14. Wilson HM,. Macrophages heterogeneity in atherosclerosis-implications for therapy. J Cell Mol Med 2010; 14: 2055-2065.
15. Pello OM, Silvestre C, De Pizzol M, Andrés V,. A glimpse on the phenomenon of macrophage polarization during atherosclerosis. Immunobiology 2011; 216: 1172-1176.
16. Leitinger N, Schulman IG,. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol 2013; 33: 1120-1126.
17. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A,. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555. (Pubitemid 35223554)
18. Mosser DM, Edwards JP,. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
19. Handberg A, Skjelland M, Michelsen AE, Sagen EL, Krohg-Sorensen K, Russell D, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke 2008; 39: 3092-3095.
20. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and Management of Peripheral Arterial Disease. A National Clinical Guideline. SIGN 89; 2006. http://www.sign.ac.uk/pdf/sign89.pdf [accessed 14 December 2013].
21. Scottish Intercollegiate Guidelines Network (SIGN). Management of Patients with Stroke or TIA: Assessment, Investigation, Immediate Management and Secondary Prevention. SIGN 108. http://www.sign.ac.uk/guidelines/fulltext/108/ [accessed 14 December 2013 ].
22. Shaikh S, Brittenden J, Lahiri R, Brown PAJ, Thies F, Wilson HM,. Macrophage subtypes in symptomatic carotid artery and femoral artery plaques. Eur J Vasc Endovasc Surg 2012; 44: 491-497.
23. Patlak CS, Blasberg RG, Fenstermacher JD,. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7. (Pubitemid 13129630)
24. Liu Y, Stewart KN, Bishop E, Marek CJ, Kluth DC, Rees AJ, et al. Unique expression of suppressor of cytokine signalling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol 2008; 180: 6270-6278.
25. 18F]flurodeoxyglucose positron-emission tomography/CT in identifying vulnerable carotid plaques. AJNR Am J Neuroradiol 2011; 32: 950-954.
26. Beer CD, Potter K, Lenzo N, Blacker D, Arnolda LF, Hankey GJ, et al. Systematic arterial inflammation, measured with 18FDG-PET is common amongst subjects with both recent and prior cerebrovascular disease. Clin Neurol Neurosurg 2012; 114: 613-616.
27. Okane K, Ibaraki M, Toyoshima H, Sugawara S, Takahashi K, Miura S, et al. 18 F-FDG accumulation in atherosclerosis: use of CT and MR co-registration of thoracic and carotid arteries. Eur J Nucl Med Mol Imaging 2006; 33: 589-594.
28. Myers KS, Rudd JH, Hailman EP,. Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. JACC Cardiovasc Imaging 2012; 5: 38-45.
29. Menezes LJ, Kotzw CW, Agu O, Richards T, Brookes J, Goh VJ, et al. Investigating vulnerable atheroma using combined 18FDG PET/CT angiography of carotid plaque with immunohistochemical validation. J Nucl Med 2011; 52: 1698-1703.
30. Tannahil GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 2013; 496: 238-242.
31. Folco JE, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages. JACC Cardiovasc Imaging 2011; 58: 603-614.
32. Martín-Ventura JL, Blanco-Colio LM, Gõmez-Hernández A, Muñoz-García B, Vega M, Serrano J, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005; 36: 1796-1800. (Pubitemid 41098781)
33. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-1831. (Pubitemid 44648621)
34. Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multi-center FDG-PET/CT feasibility study. J Am Coll Cardiol 2013; 62: 909-917.
35. Graebe M, Borgwardt L, Højgaard L, Sillesen H, Kjaer A,. When to image carotid plaque inflammation with FDG PET/CT. Nucl Med Commun 2010; 31: 773-779.
36. 18F]fluorodeoxyglucose. Methods 2002; 27: 218-225.
37. Grønholdt ML, Nordestgaard BG, Bentzon J, Wiebe BM, Zhou J, Falk E, et al. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. J Vasc Surg 2002; 35: 137-145. (Pubitemid 44725782)
38. Herisson F, Heymann MF, Chétiveaux M, Charrier C, Battaglia S, Pilet P, et al. Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis 2011; 216: 348-354.
39. Saam T, Rominger A, Wolpers S, Nikolaou K, Rist C, Greif M, et al,. Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study. Eur J Nucl Med Mol Imaging 2010; 37: 1203-1212.
40. Choi YS, Youn HJ, Chung WB, Hwang HJ, Lee DH, Park CS, et al. Uptake of F-18 FDG and ultrasound analysis of carotid plaques. J Nucl Cardiol 2011; 18: 267-272.
41. Menezes LJ, Kayani I, Ben-Haim S, Hutton B, Ell PJ, Groves AM,. What is the natural history of 18FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque. Atherosclerosis 2012; 211: 136-140.
42. Rudd J, Myers K, Bansilal S, Machac J, Woodward M, Fuster V, et al. The relationship between regional arterial inflammation, calcification, risk factors and biomarkers: a prospective FDG PET/CT imaging study. Circ Cardiovasc Imaging 2009; 2: 107-115.